New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration
SHANGHAI, Aug. 12, 2026 /PRNewswire/ -- Laekna (2105.HK) announced today that the New Drug Application (NDA) for LAE002 (afuresertib) has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration...
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity
The collaboration will accelerate the global development of LAE102, a novel Activin Receptor Type 2 A (ActRII A ) Antagonistic Monoclonal Antibody (mAb) for muscle-preserving weight loss in Obesity LOS ANGELES, Nov. 20, 2024 /PRNewswire/ -- Laekna,...